UEG Week: A new course of treatment combined with semaglutide can eliminate the dependence of patients with type 2 diabetes on insulin | Global Corporate News |

vineOctober 14, 2024 /PRNewswire/ — Breakthrough research presented today at UEG Week 2024 reveals a promising new treatment strategy for type 2 diabetes (T2D) that could significantly reduce or even prevent eliminate the need for insulin therapy.

Thanks to this innovative method, which combines a new course of treatment called ReCET (Re-Cellularization via Electroporation Therapy) with Semaglutide, 86% of patients no longer needed insulin treatment.

422 million people worldwide suffer from T2D, and obesity is one of the important risk factors for the disease. Although insulin therapy is commonly used to control blood sugar levels in people with T2D, it has side effects, including the potential for weight gain and making diabetes management more difficult. . Therefore, alternative treatment strategies are needed.

The first human study included 14 participants aged 28 to 75 years with a body mass index of 24 to 40 kg/m². All participants underwent ReCet, a treatment designed to improve the body’s sensitivity to its own insulin, under deep sedation. After this treatment, participants followed an isocaloric liquid diet for two weeks, after which the dose of semaglutide was gradually increased to 1 mg per week.

Notably, 86% of participants (12 of 14) no longer needed insulin treatment at the 6- and 12-month follow-up, and this success continued over the 24-month follow-up period. Under these conditions, all patients were able to maintain glycemic stability with HbA1c levels below 7.5%.

The highest dose of semaglutide was well tolerated by 93% of participants, with one person able to increase to the highest dose due to nausea. All patients successfully completed the RecET course, and no adverse effects were reported.

Lead author of the study Celine Busch “These results are very encouraging and show that ReCet is a safe and feasible method that, when combined with semaglutide, can eliminate the need for insulin therapy,” said Dr.

Unlike drug therapy, which requires medication to be taken on time every day, ReCET does not require medication to be taken on time, which may solve the main problem in T2D management requires patients to continue taking medication on time. In addition, this treatment modifies the disease: it improves the patient’s sensitivity to their own (basic) insulin and addresses the underlying cause of the disease; currently available drug treatments only control the disease at best. “

“We’re currently doing the EMINENT-2 trial and we’re using the same inclusion/exclusion criteria and giving semaglutide, but using sham surgery or ReCET.